Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $250.00 at Mizuho

Palvella Therapeutics (NASDAQ:PVLA) had its price target increased by Mizuho from $205.00 to $250.00 in a report published on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Several other research analysts also recently weighed in on PVLA. Truist Financial set a $210.00 price target on Palvella Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a research report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. UBS Group restated a “buy” rating and set a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Palvella Therapeutics presently has an average rating of “Buy” and an average price target of $176.44.

Palvella Therapeutics Trading Up 6.8%

Palvella Therapeutics stock opened at $128.60 on Wednesday. The business’s 50 day simple moving average is $92.78 and its 200 day simple moving average is $78.86. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $129.32. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -48.90 and a beta of -0.16.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Group One Trading LLC raised its position in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after buying an additional 433 shares in the last quarter. Archer Investment Corp bought a new position in Palvella Therapeutics in the 3rd quarter worth about $28,000. Bank of America Corp DE raised its holdings in shares of Palvella Therapeutics by 12.3% in the 3rd quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock valued at $294,000 after acquiring an additional 515 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Palvella Therapeutics by 8.7% in the 4th quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after acquiring an additional 528 shares in the last quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA topline results show strong efficacy and tolerability for QTORIN™ 3.9% rapamycin in microcystic lymphatic malformations; company plans an NDA submission in H2 2026 — a potential first-ever FDA‑approved therapy for this rare condition. Phase 3 SELVA Results
• Positive Sentiment: Several sell‑side firms raised price targets and reiterated buy/outperform ratings after the Phase 3 readout (examples include Mizuho, BTIG and Chardan), which supports upside expectations and likely boosted buying interest. Analyst Coverage
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 per share to raise roughly $200M (plus a 30‑day option for 240k additional shares). Proceeds intended for QTORIN program development and general corporate purposes — this improves cash runway but increases share supply. Offering Pricing
• Negative Sentiment: Short interest rose ~22% in February to ~1.67M shares (~17.8% of float) with a ~5.5 days-to-cover ratio — elevated short positions can amplify volatility and create short-covering spikes or pressure depending on flow. (internal short‑interest report)
• Negative Sentiment: Insider activity shows recent sales (no insider buys reported in past 6 months), which some investors view as a negative signal on timing of share sales around the rally. (internal insider activity data)

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.